← All Press Releases

Assessing, Valuing, and Commercializing IP Assets at Life Sciences IP Due Diligence Conference in Boston

September 14, 2019

American Conference Institute’s 3rd Annual Summit on Life Sciences IP Due Diligence, carded for November 14 and 15 in Boston, will be a one-of-a-kind, interactive forum where top diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis. Thought leaders from top life sciences companies including Celgene, Pfizer, Roche and Novartis Institutes for BioMedical Research will convene to share their proven strategies and network with attendees.

The continued success of a life science company hinges upon successful partnerships — There are many corporate transactions involving life sciences IP that necessitate conducting due diligence. For example, you may be asked to engage your team members in the face of a merger or acquisition, an IPO, venture capital financing, in-licensing, partnering, co-development, or distribution agreements. How you structure your diligence is entirely dependent upon your objectives.

The 2019 program is extremely comprehensive and will include newly designed think tanks will allow participants to:

  • Tailor life sciences IP due diligence checklist for 2020
  • Learn firsthand from industry thought leaders on how to perfect the FTO search
  • Analyze the latest filings, rulings and legislative developments impacting life sciences IP due diligence
  • Develop strategies for assessing, valuing and commercializing IP assets

This event is known to provide the most current, comprehensive information and advice on structuring and managing life sciences IP due diligence, in an environment that will provide incomparable networking opportunities with the players driving the year’s top transactions.

Confirmed faculty from top life sciences companies include:

Heather Boussios
Assistant General Counsel and Head of Intellectual Property, Legal Department
Aptevo Therapeutics

Ryan M. Daniel
Acting Chief Patent Counsel
Fresenius Kabi USA

Sylvia Georges Evangelinos
Senior Patent Attorney
Novartis Institutes for BioMedical Research (NIBR)

Rebecca Goodman
Senior Corporate Counsel

Philippe Edouard
Senior Director Intellectual Property, Legal
Takeda Pharmaceutical

Olga Kay
Senior Patent Counsel

Donna Meuth
Associate General Counsel, Intellectual Property
Eisai Inc.

Jeffrey N. Myers
Vice President & Assistant General Counsel
Pfizer Inc.

Ryan M. Daniel
Acting Chief Patent Counsel
Fresenius Kabi USA

Timothy Witkowski
Global Head, Chemistry Patents
Novartis Institutes for BioMedical Research (NIBR)

Marina Volin
VP, Head of Legal and IP
Kintai Therapeutics

Jen Sieczkiewicz Zarutskie
VP, Chief Intellectual Property Counsel
Wave Life Sciences